Compare AbbVie Inc (ABBV) vs Phillips 66 (PSX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Phillips 66 — how do they compare? AbbVie Inc trades at $253.85 (market cap $449.91B), while Phillips 66 trades at $186.77 (market cap $71.70B). The key difference: AbbVie Inc is far larger — about 6.3× Phillips 66's market cap, and Phillips 66 pays the higher dividend (2.84%). Which is the better fit depends on your goals.
| ABBV | PSX | |
|---|---|---|
Market Cap | $449.91B | $71.70B |
Sector | Health | Energy |
52-Week High | $261.07 | $188.28 |
52-Week Low | $184.85 | $118.37 |
Enterprise Value | $513.38B | $93.68B |
Dividend Yield | 2.72% | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Phillips 66 (PSX) trades at $178.84, up 1.37% with a bullish technical signal and strong analyst consensus. The stock shows improving fundamentals with recent earnings beats, a 3.07% net margin, and attractive valuation at P/E 17.52 and P/S 0.54. Recent news highlights resilience amid softer oil prices, supported by diversified operations and a $1.27 dividend payment.
Outlook remains positive with a $190.38 price target, though risks include refining volatility from Hormuz disruptions and declining revenue trends. The stock offers value through stable cash flow and dividend income, but investors should monitor geopolitical impacts on earnings and energy market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
